HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.

Abstract
Although infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility (SA-RVS) have been reported from a number of countries, including Australia, the optimal therapy is unknown. We reviewed the clinical features, therapy, and outcome of 25 patients with serious infections due to SA-RVS in Australia and New Zealand. Eight patients had endocarditis, 9 had bacteremia associated with deep-seated infection, 6 had osteomyelitis or septic arthritis, and 2 had empyema. All patients had received vancomycin before the isolation of SA-RVS, and glycopeptide treatment had failed for 19 patients (76%). Twenty-one patients subsequently received active treatment, which was effective for 16 patients (76%). Eighteen patients received linezolid, which was effective in 14 (78%), including 4 patients with endocarditis. Twelve patients received a combination of rifampicin and fusidic acid. Surgical intervention was required for 15 patients (60%). Antibiotic therapy, especially linezolid with or without rifampicin and fusidic acid, in conjunction with surgical debulking is effective therapy for the majority of patients with serious infections (including endocarditis) caused by SA-RVS.
AuthorsBenjamin P Howden, Peter B Ward, Patrick G P Charles, Tony M Korman, Andrew Fuller, Philipp du Cros, Elizabeth A Grabsch, Sally A Roberts, Jenny Robson, Kerry Read, Narin Bak, James Hurley, Paul D R Johnson, Arthur J Morris, Barrie C Mayall, M Lindsay Grayson
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 38 Issue 4 Pg. 521-8 (Feb 15 2004) ISSN: 1537-6591 [Electronic] United States
PMID14765345 (Publication Type: Journal Article)
Chemical References
  • Acetamides
  • Anti-Infective Agents
  • Oxazolidinones
  • Vancomycin
  • Linezolid
  • Rifampin
Topics
  • Acetamides (therapeutic use)
  • Aged
  • Aged, 80 and over
  • Anti-Infective Agents (therapeutic use)
  • Female
  • Humans
  • Linezolid
  • Male
  • Methicillin Resistance
  • Microbial Sensitivity Tests
  • Middle Aged
  • Oxazolidinones (therapeutic use)
  • Rifampin (therapeutic use)
  • Staphylococcal Infections (drug therapy)
  • Staphylococcus aureus (drug effects)
  • Treatment Outcome
  • Vancomycin
  • Vancomycin Resistance

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: